Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 41Terminated 21Recruiting 12Unknown 9Active not recruiting 9Withdrawn 5Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1

Interventions

Cisplatin 122Carboplatin 120Drug Therapy 104Bevacizumab 101Capecitabine 96Oxaliplatin 95Radiotherapy 92Gemcitabine 88Paclitaxel 87tislelizumab 84Cyclophosphamide 83Specimen Handling 80pembrolizumab 76toripalimab 66Magnetic Resonance Spectroscopy 63Fluorouracil 61sintilimab 58Injections 57anlotinib 51Docetaxel 51Surgical Procedures, Operative 48130-nm albumin-bound paclitaxel 48fludarabine 45Pemetrexed 43Standard of Care 42Biopsy 42venetoclax 41Irinotecan 41lenvatinib 40Leucovorin 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Hydroxychloroquine × Clear all
NCT07061717 2025-07-11

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Not yet recruiting
474 enrolled
Breast

Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡